Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas

Published

on

  • Collaboration enables Kyowa Kirin’s R&D team to access InveniAI’s data-driven discovery platform in expanded therapeutic areas
  • InveniAI’s AlphaMeld® platform to provide unique Translational Edge for prioritizing product concepts across disease states
  • InveniAI will receive a committed annual research funding fee for the duration of the collaboration term and obtain rights to receive milestone payments and royalties on sales from Kyowa Kirin

GUILFORD, Conn. and TOKYO, Dec. 16, 2021 (GLOBE NEWSWIRE) — InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, expanded their longstanding relationship with a new, multiple drug discovery agreement. The collaboration will provide Kyowa Kirin with access to InveniAI’s AI Innovation Lab and AI Technology Platform, AlphaMeld®, to expand the scope of Kyowa Kirin’s drug discovery programs.

The agreement builds on an ongoing partnership between InveniAI and Kyowa Kirin that began in 2018. The collaboration enables Kyowa Kirin to access InveniAI’s AI technology platform, AlphaMeld®, its AI Innovation Lab, and a dedicated team of experts to drive drug discovery efforts across Kyowa Kirin’s therapeutic areas, platforms, and modalities. InveniAI and Kyowa Kirin are now standing at the intersection of state-of-the-art biotechnology and digital technology. Both scientists will work together more interactively to generate innovative drug candidates.

Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin, said, “We are excited about the strategic expansion of our partnership, as it is designed to seamlessly integrate InveniAI’s AI capabilities with our therapeutic platforms to facilitate the discovery of valuable new therapies for patients. Our collaboration, to date, is a testament to the importance of a data-driven approach, and through our partnership with InveniAI, we are embracing the undeniable advantage of technology-aided drug discovery and development.”

“We are pleased to expand our collaboration with Kyowa Kirin, with whom we share a common philosophy of leveraging data and technology to de-risk drug development and deliver better therapies to patients more efficiently. By leveraging our longstanding relationship and combined capabilities – including drug discovery and development infrastructure, and a proven AI platform –we believe we can rapidly achieve this objective,” said Krishnan Nandabalan, Ph.D., President and CEO, InveniAI LLC. “InveniAI is the only AI company with a track record that includes an AI-identified candidate that has undergone successful Phase 3 trials and an NDA submission, in addition to ten other programs at various stages of development. We remain excited about harnessing the potential of this platform for both industry partnerships and our internal drug portfolio.”

Under the terms of the collaboration, InveniAI will receive a committed annual research funding fee for the duration of the collaboration term and obtain rights to receive milestone payments and royalties on sales from Kyowa Kirin.

About AlphaMeld®
AlphaMeld® is an AI-based platform powered by machine learning algorithms that accelerates innovation by identifying alpha signals for targets, drugs, and healthcare products and technologies. The platform generates testable hypotheses by leveraging the TranslationalEdge and ModalityFit AI tools we have developed that take into account an ideal mode of pharmacotherapy (antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities), disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies while factoring in medical, scientific, strategic, and commercial considerations. AlphaMeld® operates in real-time and in a rapidly changing and diverse data environment.

About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, the company applies cutting-edge science, including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas, including Nephrology, Oncology, Immunology/Allergy, and Neurology. Across our four regions – Japan, Asia Pacific, North America, and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com.

About InveniAI®

InveniAI® LLC, based in Guilford, Conn., is a global leader pioneering the application of Artificial Intelligence (AI) and Machine Learning (ML) to transform innovation across drug discovery and development by identifying and accelerating transformative therapies for diseases with unmet medical needs. The Company leverages, AlphaMeld®, an AI- and ML-powered platform, to harness petabytes of disparate data sets to recognize and unlock value for drug discovery and development. Numerous industry collaborations in Big Pharma, Specialty Pharma, Biotech, and Consumer Healthcare showcase the value of leveraging our technology to meld human experience and expertise with the power of machines to augment R&D decision-making across all major therapeutic areas. The Company leverages AlphaMeld® to augment and accelerate drug discovery programs for industry partners and an internal portfolio of programs addressing highly debilitating, functional, chronic inflammatory, and autoimmune gastrointestinal (GI) disorders driven by dysregulation of the gut-brain axis.

For more information, please visit: www.inveniai.com.| LinkedIn:@inveniai| Twitter: https://twitter.com/Inveni_AI

Contact
InveniAI LLC
Anita Ganjoo, Ph.D.
Corporate Communications
+1 203 643 8041
E-mail: [email protected]

Kyowa Kirin Co., Ltd.
Hiroki Nakamura
Media
+81-3-5205-7205
E-mail: [email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Jean-Michel Jarre is world’s first passenger to take off in KleinVision’s flying AirCar

Published

on

jean-michel-jarre-is-world’s-first-passenger-to-take-off-in-kleinvision’s-flying-aircar

PIESTANY, Slovakia, April 24, 2024 /PRNewswire/ — Godfather of electronic music and innovator Jean-Michel Jarre becomes world’s first passenger to take off in KleinVision’s flying AirCar in preparation for Starmus Opening Concert also Featuring Sir Brian May of Queen.

KleinVision’s AirCar took to the skies with electronic music pioneer, Jean-Michel Jarre as its first passenger this month, signaling a new era of transportation innovation. AirCar, which received the Certificate of Airworthiness in January 2022, has already logged an impressive 130 flight hours and over 520 takeoffs.
“It is like being in a Jules Verne book, but for real! One second you speak to the driver, and next, you are up there in the air – an amazing experience!” said Jean-Michel Jarre after completing two flights in the AirCar at Piestany international airport.
The artist’s excitement was palpable as he marveled at the futuristic experience, perfectly reflecting the theme of his upcoming Starmus opening concert, ‘The Bridge from the Future’, powered by ESET, global digital security leader.
“AirCar addition to Starmus is a fantastic complement to our festival experience,” said Garik Israelian, PhD, astrophysicist at the Institute of Astrophysics of the Canary Islands and co-founder of Starmus, alongside Sir Brian May. “It mirrors the exhilarating journey we embark on, starting with Jean-Michel and Brian’s monumental concert that propels us to new heights, soaring alongside artists and inspiring thinkers like Jane Goodall, and coming back to Earth with the wisdom of astronaut Chris Hadfield once the festival concludes.”
“AirCar will not only be part of the Starmus opening concert, it will also be showcased at Starmus Camp, which, together with the Stephen Hawking Medal Ceremony and nine Nobelists giving lectures, will turn Bratislava into the world capital of science.”
Film director Todd Douglas Miller, Emmy Award-winning filmmaker of Apollo 11, captured the historic moment as he filmed the AirCar soaring at 2500 feet. “It looks impossible. It looks like it’s doing something it should not be doing!” Miller remarked, highlighting the groundbreaking nature of AirCar.
Professor Stefan Klein, inventor and pilot, expressed his pride as Jean-Michel became the inaugural passenger on the groundbreaking aircraft. “From dreams to reality, we have taken flight together with Jean-Michel, opening a new era of transportation with a touch of magic,” said Klein, moments before completing another successful intercity flight from Piestany to Nitra.
Anton Zajac, co-founder of KleinVision and ESET, lauded the advancement the AirCar represents in blurring the lines between roads and skies. “We are bridging the gap between the road and the sky, giving cars the freedom they symbolized 50 years ago,” Zajac remarked.
The flights took place in Piestany, Slovakia, and marked a momentous step towards a future where terrestrial and aerial travel seamlessly converge.
To see the short footage of the flight, click here. 
Photo – https://mma.prnewswire.com/media/2395057/Klein_Vision.jpg

View original content:https://www.prnewswire.co.uk/news-releases/jean-michel-jarre-is-worlds-first-passenger-to-take-off-in-kleinvisions-flying-aircar-302124769.html

Continue Reading

Artificial Intelligence

SUPCON Unveils Groundbreaking Products in June, Including the World’s First UCS

Published

on

supcon-unveils-groundbreaking-products-in-june,-including-the-world’s-first-ucs

HANGZHOU, China, April 24, 2024 /PRNewswire/ — In June, SUPCON (688777) is poised to launch two groundbreaking products in Singapore: the world’s first UCS (Universal Control System) and TPT (Time-Series Pre-trained Transformer), the first time-series model in the process industry.

UCS, a revolutionary innovation from SUPCON, is set to revolutionize the 50-year-old DCS architecture, promising to eliminate traditional control cabinets.
TPT, as the pioneering time-series model in the process industry, will replace numerous traditional industrial apps and overcome unsolved industrial challenges.
SUPCON, founded in 1999, is a prominent global provider of intelligent manufacturing solutions for process industries. The company is committed to the development and application of AI technology through the integration of advanced products and extensive industry know-how. With a global customer exceeding 30,000, SUPCON’s products address all needs across over 50 countries and regions, encompassing sectors like oil & gas, refinery & petrochemical, chemical, etc. Aiming at high-quality and sustainable development, SUPCON is on the way to facilitate the automation and intelligentization of the global process industry.
In 2023, SUPCON’s core products, the Distributed Control System (DCS) and the Safety Instrumented System (SIS), both claimed the top market share position in China, achieving respective figures of 37.8% and 33.7%. Notably, the DCS has maintained the No.1 position for a consecutive 13th year.

View original content:https://www.prnewswire.co.uk/news-releases/supcon-unveils-groundbreaking-products-in-june-including-the-worlds-first-ucs-302125406.html

Continue Reading

Artificial Intelligence

Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation

Published

on

automation-anywhere-appoints-tim-mcdonough-as-chief-marketing-officer-to-drive-global-awareness-and-growth-for-the-leader-in-ai-powered-automation

SAN JOSE, Calif., April 23, 2024 /PRNewswire/ — Automation Anywhere, a leader in AI-powered automation solutions, announced that AI marketing leader ﷟Tim McDonough joined the company as chief marketing officer (CMO). McDonough, who brings more than two decades of experience in driving growth across startups and Fortune 100 companies, will shape and lead Automation Anywhere’s global brand and growth strategies and go-to-market functions.

 
McDonough joins Automation Anywhere from Intel, where he recently served as vice president and CMO of AI and data centers. McDonough oversaw the transformation of the $14 billion-plus business unit, while guiding the company’s strategy and positioning in the AI market.
“Tim joins us at an incredible time in our journey as we experience a new phase of growth ignited by the transformative benefits of our generative AI process automation models that are transforming our customers’ businesses,” said Mihir Shukla, CEO, Automation Anywhere. “Tim’s impressive experience will be instrumental in our efforts to empower organizations to achieve amazing results by automating more than forty percent of workflows and tasks, and saving millions, even billions, of dollars.”
Prior to Intel, McDonough held executive roles at leading technology companies, including Unity Technologies, Qualcomm, and Microsoft. McDonough’s track record of enterprise and C-suite marketing spans developed and emerging technologies, including AI tools, applications, software-as-a-service (SaaS) solutions, and developer ecosystems.
“I’m looking forward to helping lead Automation Anywhere through its next phase growth as it helps companies transform their business,” said McDonough. “Seeing how customers are innovating with Automation Anywhere’s platform demonstrated to me the incredible market opportunity we have. When you combine automation with generative AI, customers can now go beyond task or departmental impact and automate at an enterprise level, empowering companies and employees to do their very best work.”
McDonough’s appointment comes at a time of remarkable opportunity for the company, marked by Automation Anywhere’s recent record-breaking fourth-quarter performance, continued profitability, and strong outlook in its current fiscal year. Last quarter, Automation Anywhere reported 50 percent growth in large enterprise deals from the previous quarter, highlighting the company’s momentum and strong market position.  
About Automation Anywhere  
Automation Anywhere is the leader in AI-powered process automation that puts AI to work across organizations. The company’s Automation Success Platform is powered with generative AI and offers process discovery, RPA, end-to-end process orchestration, document processing, and analytics, with a security and governance-first approach. Automation Anywhere empowers organizations worldwide to unleash productivity gains, drive innovation, improve customer service, and accelerate business growth. The company is guided by its vision to fuel the future of work by unleashing human potential through AI automation. Learn more at http://www.automationanywhere.com/.  
Engage with Automation Anywhere  
WebinarsLinkedInThreadsFacebookInstagramPhoto – https://mma.prnewswire.com/media/2395055/Tim_Headshot.jpgLogo – https://mma.prnewswire.com/media/2383572/4665982/Automation_Anywhere_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/automation-anywhere-appoints-tim-mcdonough-as-chief-marketing-officer-to-drive-global-awareness-and-growth-for-the-leader-in-ai-powered-automation-302125158.html

Continue Reading

Trending